The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: Effects on the Locus coerules

Journal of Neurochemistry

Volumn 121, Issue 2, 2012, Pages 206-216

  Polak, Paul E ^a,b   Kalinin, Sergey ^a,b   Braun, Davib ^a,b   Sharp, Anthony ^a,b   Lin, Shao X ^a,b   Feinstein, Douglas L ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Glial cells; Locus coeruleus; Noradrenaline; Tyrosine hydroxylase

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NORADRENALIN; TYROSINE 3 MONOOXYGENASE; VINDEBURNOL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DYSFUNCTION; BRAIN FUNCTION; CELL ACTIVATION; CEREBELLUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HYPERTROPHY; LOCUS CERULEUS; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT RESPONSE;

ANIMALS; CEREBELLUM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; LOCUS COERULEUS; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NEUROGLIA; NOREPINEPHRINE; RNA, MESSENGER; SURVIVAL; T-LYMPHOCYTES; TYROSINE 3-MONOOXYGENASE; VINCAMINE;

MUS;

EID: 84862823188     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2012.07673.x     Document Type: Article

References (53)

1. Adolfsson R., Gottfries C. G., Roos B. E. and Winblad B. (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135, 216-223. (Pubitemid 9244805)
2. Barkhatova V. P., Zavalishin I. A., Askarova L. S., Shavratskii V. K. and Demina E. G. (1998) Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav. Physiol. 28, 341-344. (Pubitemid 128695890)
3. Barzaghi F., Dragonetti M., Formento M. L. and Boissier J. R. (1985) Effects of the new eburnamenine derivative RU 24722 on EEG recovery and cerebral energy metabolism after complete ischemia. Arzneimittelforschung 35, 472-477. (Pubitemid 15155406)
4. Bezin L., Marcel D., Desgeorges S., Pujol J. F. and Weissmann D. (2000) Singular subsets of locus coeruleus neurons may recover tyrosine hydroxylase phenotype transiently expressed during development. Brain Res. Mol. Brain Res. 76, 275-281.
5. Bondareff W., Mountjoy C. Q., Roth M., Rossor M. N., Iversen L. L., Reynolds G. P. and Hauser D. L. (1987) Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1, 256-262.
6. Bracha H. S., Garcia-Rill E., Mrak R. E. and Skinner R. (2005) Postmortem locus coeruleus neuron count in three American veterans with probable or possible war-related PTSD. J. Neuropsychiatry Clin. Neurosci. 17, 503-509. (Pubitemid 41790051)
7. Debeir T., Marien M., Ferrario J., Rizk P., Prigent A., Colpaert F. and Raisman-Vozari R. (2004) In vivo upregulation of endogenous NGF in the rat brain by the alpha2-adrenoreceptor antagonist dexefaroxan: potential role in the protection of the basalocortical cholinergic system during neurodegeneration. Exp. Neurol. 190, 384-395. (Pubitemid 39516939)
8. Debure L. I., Moyse E., Fevre-Montange M., Hardin H., Belin M. F., Rousset C., Pujol J. F. and Weissmann D. (1992) Somatotopic organization of tyrosine hydroxylase expression in the rat locus coeruleus: long term effect of RU24722. Brain Res. 581, 19-32.
9. Ekblom J., Aquilonius S. M. and Jossan S. S. (1993) Differential increases in catecholamine metabolizing enzymes in amyotrophic lateral sclerosis. Exp. Neurol. 123, 289-294. (Pubitemid 23328920)
10. Euvrard C. and Boissier J. R. (1981) The neurochemical profile of RU 24722 a new specific and reversible depletory of noradrenaline. Abstracts of the UIPHAR 8th International Congress of Pharmacology, 384.
11. Feinstein D. L., Galea E., Gavrilyuk V., Brosnan C. F., Whitacre C. C., Dumitrescu-Ozimek L., Landreth G. E., Pershadsingh H. A., Weinberg G. and Heneka M. T. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694-702. (Pubitemid 34568847)
12. Frohman E. M., Vayuvegula B., Gupta S. and van den N. S. (1988) Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc. Natl. Acad. Sci. USA 85, 1292-1296. (Pubitemid 18073995)
13. Galea E. and Feinstein D. L. (1999) Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 13, 2125-2137.
14. Ghiani C. A., Eisen A. M., Yuan X., DePinho R. A., McBain C. J. and Gallo V. (1999) Neurotransmitter receptor activation triggers p27(Kip1)and p21(CIP1) accumulation and G1 cell cycle arrest in oligodendrocyte progenitors. Development 126, 1077-1090. (Pubitemid 29142014)
15. Heneka M. T., Ramanathan M., Jacobs A. H. et al. (2006) Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343-1354. (Pubitemid 43237005)
16. Hong J., Shu-Leong H., Tao X. and Lap-Ping Y. (1998) Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport 9, 2861-2864. (Pubitemid 28435178)
17. Jardanhazi-Kurutz D., Kummer M. P., Terwel D., Vogel K., Dyrks T., Thiele A. and Heneka M. T. (2010) Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int. 57, 375-382.
18. Jeon K. I., Xu X., Aizawa T., Lim J. H., Jono H., Kwon D. S., Abe J., Berk B. C., Li J. D. and Yan C. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 107, 9795-9800.
19. Kalinin S., Feinstein D. L., Xu H. L., Huesa G., Pelligrino D. A. and Galea E. (2006) Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur. J. Neurosci. 24, 3393-3400. (Pubitemid 44952606)
20. Kalinin S., Gavrilyuk V., Polak P. E., Vasser R., Zhao J., Heneka M. T. and Feinstein D. L. (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28, 1206-1214. (Pubitemid 46810064)
21. Kalinin S., Polak P. E., Lin S. X., Sakharkar A. J., Pandey S. C. and Feinstein D. L. (2011) The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging (in press, DOI: 10.1016/j.neurobiolaging. 2011.04.012.).
22. Khoruzhaia T. A. and Saakov B. A. (1975) [Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis]. Biull. Eksp. Biol. Med. 79, 80-82.
23. Krenger W., Honegger C. G., Feurer C. and Cammisuli S. (1986) Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J. Neurochem. 47, 1247-1254. (Pubitemid 16032489)
24. Labatut R., Richard F., Milne B., Quintin L., Lecestre D. and Pujol J. F. (1988) Long-term effects of RU24722 on tyrosine hydroxylase of the rat brain. J. Neurochem. 51, 1367-1374. (Pubitemid 18264353)
25. Madrigal J. L., Feinstein D. L. and Dello R. C. (2005) Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res. 81, 390-396. (Pubitemid 41359293)
26. Madrigal J. L., Kalinin S., Richardson J. C. and Feinstein D. L. (2007) Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J. Neurochem. 103, 2092-2101. (Pubitemid 350126619)
27. Mann D. M. and Yates P. O. (1983) Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol. Appl. Neurobiol. 9, 3-19. (Pubitemid 13125944)
28. Mann D. M., Lincoln J., Yates P. O., Stamp J. E. and Toper S. (1980) Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136, 533-541. (Pubitemid 10120395)
29. Marcel D., Raison S., Bezin L., Pujol J. F. and Weissmann D. (1998) Plasticity of tyrosine hydroxylase gene expression within BALB/C and C57Black/6 mouse locus coeruleus. Neurosci. Lett. 242, 77-80. (Pubitemid 28082997)
30. Marien M. R., Colpaert F. C. and Rosenquist A. C. (2004) Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45, 38-78. (Pubitemid 38520015)
31. Marin C. and Obeso J. A. (2010) Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment. Int. Rev. Neurobiol. 95, 191-205.
32. Markianos M., Koutsis G., Evangelopoulos M. E., Mandellos D., Karahalios G. and Sfagos C. (2009) Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J. Neurochem. 108, 158-164.
33. McNamee E. N., Ryan K. M., Griffin E. W., Gonzalez-Reyes R. E., Ryan K. J., Harkin A. and Connor T. J. (2010) Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration. Brain Behav. Immun. 24, 660-671.
34. Minghetti L., Nicolini A., Polazzi E., Creminon C., Maclouf J. and Levi G. (1997) Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 19, 152-160. (Pubitemid 27094132)
35. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., Baker G. B. and Kerr B. J. (2011) The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav. Immun. 25, 1677-1688.
36. Olpe H. R. and Steinmann M. W. (1982) The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons. J. Neural Transm. 55, 101-109.
37. O'Sullivan J. B., Ryan K. M., Harkin A. and Connor T. J. (2010) Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J. Neuroimmunol. 220, 34-42.
38. Polak P. E., Kalinin S. and Feinstein D. L. (2011) Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 134, 665-677.
39. Remy S., Naveilhan P., Brachet P. and Neveu I. (2001) Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J. Neurosci. Res. 64, 242-251. (Pubitemid 32385692)
40. Salehi A., Faizi M., Colas D. et al. (2009) Restoration of norepinephrine- modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7ra17.
41. Samantaray S., Knaryan V. H., Butler J. T., Ray S. K. and Banik N. L. (2008) Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. J. Neurochem. 104, 1309-1320. (Pubitemid 351293347)
42. Sharp A. J., Polak P. E., Simonini V., Lin S. X., Richardson J. C., Bongarzone E. R. and Feinstein D. L. (2008) P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J. Neuroinflamm. 5, 33.
43. Simonini M. V., Polak P. E., Sharp A., McGuire S., Galea E. and Feinstein D. L. (2010) Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune. Pharmacol. 5, 252-259.
44. Szabo C., Hasko G., Zingarelli B., Nemeth Z. H., Salzman A. L., Kvetan V., Pastores S. M. and Vizi E. S. (1997) Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide produciton and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 90, 95-100. (Pubitemid 27008395)
45. Szatmari S. Z. and Whitehouse P. J. (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database. Syst. Rev. Issue 1, Art. No. CD003119. DOI: 10.1002/14651858.CD003119.
46. Takeda N., Yamatodani A., Watanabe T. and Wada H. (1984) Effect of a new eburnamine derivative, RU 24722, on the turnover of monoamines in mouse brain: selective and reversible decrease of noradrenaline. Eur. J. Pharmacol. 106, 357-362. (Pubitemid 15210625)
47. Tesseris J., Roggen G., Caracalos A. and Triandafillou D. (1975) Effects of vincamin on cerebral metabolism. Eur. Neurol. 13, 195-202.
48. Tomlinson B. E., Irving D. and Blessed G. (1981) Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci. 49, 419-428. (Pubitemid 11184187)
49. Traver S., Salthun-Lassalle B., Marien M., Hirsch E. C., Colpaert F. and Michel P. P. (2005) The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol. Pharmacol. 67, 1882-1891. (Pubitemid 41007770)
50. Trojanowski J. Q., Atkinson B. and Lee V. M. (1986) An immunocytochemical study of normal and abnormal human cerebrospinal fluid with monoclonal antibodies to glial fibrillary acidic protein. Acta Cytol. 30, 235-239. (Pubitemid 16061826)
51. Vas A. and Gulyas B. (2005) Eburnamine derivatives and the brain. Med. Res. Rev. 25, 737-757. (Pubitemid 41447149)
52. Weissmann D., Labatut R., Gillon J., Richard F. and Pujol J. (1988) [Measurement of brain tyrosine hydroxylase concentrations by quantitative autoradiography after transfer of soluble proteins to nitro-cellulose]. C. R. Acad. Sci. III 306, 457-460.
53. White S. R., Bhatnagar R. K. and Bardo M. T. (1983) Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J. Neurochem. 40, 1771-1773. (Pubitemid 13106963)